DelveInsight's“ Obesity Pipeline Insigh t 2025 ” report provides comprehensive insights about 80+ companies and 100+ pipeline ...

If you’ve been taking Ozempic or Wegovy (both of which contain the active ingredient semaglutide), you might wonder, How long ...

In 2022, over 1 billion people were affected by obesity, driving innovation in therapeutic advancements. Emerging treatments focus on appetite contro ...

Research shows promising results for a weekly injectable Parkinson's treatment that maintains consistent medication levels, ...

A once-a-week Parkinson’s injection could replace multiple daily pills, thanks to a new slow-release formulation developed by ...

Researchers have developed a long-acting weekly injection that delivers steady doses of levodopa and carbidopa, potentially transforming care for Parkinson’s disease.

PolyPid's proprietary and clinically validated, prolonged-release drug delivery technology aims to subcutaneously deliver GLP ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

A new weekly injection may soon transform how millions manage Parkinson’s disease. For over 8.5 million people living with ...

Oxyntomodulin (OXM) is a peptide hormone released by intestinal L cells after food intake. It acts as a dual agonist of glucagon-like peptide 1 (GLP-1) and glucagon receptors, regulating appetite, ...